Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Sells $19,786.77 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 6,051 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total value of $19,786.77. Following the sale, the insider now directly owns 120,986 shares in the company, valued at approximately $395,624.22. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Puma Biotechnology Stock Performance

NASDAQ:PBYI opened at $3.02 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.46 and a quick ratio of 1.38. Puma Biotechnology, Inc. has a 1 year low of $2.13 and a 1 year high of $7.73. The stock’s 50 day simple moving average is $3.91 and its two-hundred day simple moving average is $4.78. The company has a market cap of $145.68 million, a price-to-earnings ratio of 9.15 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.12. The firm had revenue of $43.80 million during the quarter, compared to analysts’ expectations of $41.53 million. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. As a group, equities analysts anticipate that Puma Biotechnology, Inc. will post 0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Puma Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Puma Biotechnology in the 1st quarter worth approximately $57,000. Ritholtz Wealth Management purchased a new position in Puma Biotechnology during the 4th quarter valued at $66,000. Crestline Management LP boosted its holdings in Puma Biotechnology by 6.5% during the 4th quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 2,135 shares during the period. Lazard Asset Management LLC boosted its holdings in Puma Biotechnology by 5,129.0% during the 1st quarter. Lazard Asset Management LLC now owns 49,466 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 48,520 shares during the period. Finally, Jump Financial LLC boosted its holdings in Puma Biotechnology by 131.7% during the 4th quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 32,510 shares during the period. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on PBYI shares. StockNews.com raised Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 12th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, June 3rd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.